USPTO serial 79437925
NANOSYRINGE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CORNWELL, ANDREA B
- Law office
- TMO LAW OFFICE 115
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with NANOSYRINGE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Micro-organisms, cultures and preparations of micro-organisms, other than for medical and veterinary use, for the targeted intracellular delivery of biological molecules; chemical products and substances for use in science and industry for the targeted intracellular delivery of biological molecules; chemical products and substances for in vitro use for the targeted intracellular delivery of biological molecules; cell cultures except for medical and veterinary purposes; chemicals for analysis in laboratories; media for cell culture for use in the biotechnological industry; cultures of cell media [other than for medical or veterinary use]; nutritive agents for processing living cells [other than for medical use] for the targeted intracellular delivery of biological molecules; biological preparations for use in cell cultures, other than for medical or veterinary use, for the targeted intracellular delivery of biological molecules; chemicals and polymers for use in the pharmaceutical industry for the targeted intracellular delivery of biological molecules; proteins for scientific research and development for the targeted intracellular delivery of biological molecules; peptide preparations for use in the manufacture of pharmaceuticals and for the targeted intracellular delivery of biological molecules; proteins for use in science for the targeted intracellular delivery of biological molecules; laboratory reagents for scientific use for the targeted intracellular delivery of biological molecules; laboratory reagents for the targeted intracellular delivery of peptides, proteins, enzymes, gene editing enzymes, antibodies or antibody fragments; genetically-encoded protein complexes capable of binding to cell-surface antigens, for delivering biological molecules to target cells, other than for medical use; genetically-encoded protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules to target cells, other than for medical use. | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations for the targeted intracellular delivery of biological molecules, drugs and therapeutic substances; pharmaceutical preparations and substances for the targeted intracellular delivery of biological molecules, drugs and therapeutic substances; pharmaceutical compositions and preparations for the targeted intracellular delivery of biological molecules, drugs and therapeutic substances; pharmaceutical preparations for intracellular delivery of drugs; veterinary preparations for intracellular delivery of drugs; pharmaceutical preparations for intracellular delivery of antibodies; veterinary preparations for intracellular delivery of antibodies; pharmaceutical preparations for intracellular delivery of enzymes; veterinary preparations for intracellular delivery of enzymes; pharmaceutical preparations for intracellular delivery of antibody fragments; veterinary preparations for intracellular delivery of antibody fragments; pharmaceutical preparations for gene editing; veterinary preparations for gene editing; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on non-viral delivery technology; veterinary preparations for intracellular delivery of therapeutic substances focused on non-viral delivery technology; pharmaceutical preparations for intracellular delivery of nucleic acids; veterinary preparations for intracellular delivery of nucleic acids; pharmaceutical preparations for intracellular delivery of proteins; veterinary preparations for intracellular delivery of proteins; pharmaceutical preparations for intracellular delivery of peptides; veterinary preparations for intracellular delivery of peptides; pharmaceutical preparations for intracellular delivery of small molecules; veterinary preparations for intracellular delivery of small molecules; pharmaceutical substances for intracellular delivery of drugs; pharmaceutical substances for gene editing; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies; pharmaceutical substances for intracellular delivery of therapeutic substances focused on non-viral delivery technology; pharmaceutical substances for intracellular delivery of nucleic acids; pharmaceutical substances for intracellular delivery of proteins; pharmaceutical preparations for intracellular delivery peptides; pharmaceutical substances for intracellular delivery of peptides; drug delivery agents for the targeted intracellular delivery of biological molecules, drugs and therapeutics; drug delivery agents that facilitate the intracellular delivery of pharmaceutical preparations; biological pharmaceuticals for the targeted intracellular delivery of biological molecules, drugs and therapeutics; drug delivery agents for delivering pharmaceuticals to target cells; agents for delivering proteins to target cells; agents for delivering peptides to target cells; bacterial preparations for pharmaceutical purposes for the targeted intracellular delivery of biological molecules, drugs and therapeutics; bacterial preparations for medical purposes for the targeted intracellular delivery of biological molecules, drugs and therapeutics; micro-organisms, bacteria and cultures and preparations of micro-organisms for medical and veterinary use; media for the storage of micro-organisms and bacteria, bacteriological cultures; nutritive substances for micro-organisms; bacterial cultures for medical and veterinary use; cultures of microorganisms for medical and veterinary use; bacterial and bacteriological preparations for medical or veterinary use for the targeted intracellular delivery of biological molecules, drugs and therapeutics; diagnostic preparations and substances; pharmaceutical and veterinary preparations and substances for the targeted intracellular delivery of biological molecules, drugs and therapeutics; diagnostic preparations and substances, all for in vivo use; cell preparations for medical and veterinary purposes, nutrients for cell cultures; living cells for medical use; genetically-encoded protein complexes capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells, for medical or veterinary use; genetically-encoded protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells, for medical or veterinary use. | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; research services relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; biotechnological research services relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; drug discovery services relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; clinical trials relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; development of pharmaceutical preparations and medicines for the targeted intracellular delivery of biological molecules, drugs and therapeutics; laboratory research services relating to pharmaceuticals for the targeted intracellular delivery of biological molecules, drugs and therapeutics; medical laboratories; medical laboratory services; medical research relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; medical research services relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; pharmaceutical drug development services relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; pharmaceutical research and development relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; research and development of vaccines and medicines relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; research of pharmaceuticals relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; research relating to medicines relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; research relating to pharmaceuticals for the targeted intracellular delivery of biological molecules, drugs and therapeutics; scientific investigations for medical purposes relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; scientific research and development relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; scientific research in the field of pharmacy relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; services for assessing the efficacy of pharmaceuticals relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; research and development in the field of drug delivery relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; research and development in the field of gene editing; scientific and technological services and research and design relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; biotechnological research services relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; drug discovery services relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; clinical trials relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; laboratory research services relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; medical research relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; pharmaceutical drug development services relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; pharmaceutical research and development relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; providing medical and scientific research information in the field of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; research and development of vaccines and medicines relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; services for assessing the efficacy of pharmaceuticals relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; research and development in the field of drug delivery relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; information, advisory and consultancy services relating to all of the aforesaid. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 10, 2026 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 10, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 5, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 18, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 18, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 11, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 10, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 3, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 2, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 27, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |